OlayemiOlajideOsiyemiMD

Infectious Disease • West Palm Beach, FL

President/CEO at Triple O Medical Services PA, Triple O Research Institute PA, Fantastic Wellness Center

Join to view full profile

Dr. Osiyemi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Osiyemi's full profile

Already have an account?

Office
2580 Metrocentre Blvd
Ste 3
West Palm Beach, FL 33407
Phone+1 561-832-6770

Fax+1 561-832-3292

Summary

Dr. Olayemi Osiyemi is an infectious disease specialist in West Palm Beach, FL and is affiliated with multiple hospitals in the area, including St. Mary’s medical center, Good Samaritan medical center, Kindred Hospital Of the Palm Beach and JFK Medical Center. He received his medical degree from University of Maryland School of Medicine and has been in practice 20 years. He is the President of Triple O Medical Services and Triple O Tesearch Institute PA. He is involved in all phases of clinical trials and has published in several peer reviewed journals. He has a phase I unit in his research organization. He hold several leadership positions and serves on several boards. He also co-owns Fantastic wound care and Wellness Center in west palm beach, FL.

Education & Training

University of Miami/Jackson Health SystemFellowship, Infectious Disease, 2000
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1995 - 1998
University of Miami/Jackson Health SystemInternship, Internal Medicine, 1995 - 1996
University of Maryland School of MedicineClass of 1995
Jacksonville State UniversityB.S., Chemistry and Mathematics, 1982 - 1985

Certifications & Licensure

FL State Medical License 1997 - 2025
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
100 Most Influential African American South Florida, 2009
Certificate of Appreciation The Department of Health of Palm Beach County, 2008
Certificate of Appreciation Worlds AIDS Day/FL Health Dept of Palm Beach County, 2005, 2008
Certificate of Appreciation Palm Beach County Medical Society, 2004, 2007
Citizen of the Year in Palm Beach County Minority Law Enforcement Council, 2003
Physician of the Month St. Mary's Medical Center, 2003
President's Certificate of Commendation University of Maryland at Baltimore, 1993
Good Conduct Medal U.S. Army, 1990
Commendation Medal Award U.S. Army, 1990
Commendation Award United Way, 1987
Join now to see all

Clinical Trials

Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens Start of enrollment: 2005 Aug 01
Completed
Phase 1
SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients Start of enrollment: 2006 Mar 01
Unknown status
Phase 2
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation Start of enrollment: 2006 Mar 31
Completed
Phase 1, Phase 2
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women Start of enrollment: 2006 Jun 01
Completed
Phase 1
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants Start of enrollment: 2006 May 01
Completed
Phase 2
Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients Start of enrollment: 2006 Jul 01
Completed
Phase 3
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir Start of enrollment: 2007 Jun 01
Completed
Phase 3
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 Start of enrollment: 2008 Aug 01
Completed
Phase 2
An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. Start of enrollment: 2004 May 01
Approved for marketing
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus Start of enrollment: 2011 Jun 01
Completed
Phase 2
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay Start of enrollment: 2014 Mar 01
Completed
Study of Debio 1450 for Bacterial Skin Infections Start of enrollment: 2015 May 01
Completed
Phase 2
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
Completed
Phase 3
Antibiotic Prophylaxis in Open Fractures Start of enrollment: 2016 Dec 01
Unknown status
Phase 4
Preventing Infections in Orthopaedic Patients Start of enrollment: 2016 Nov 01
Unknown status
Join now to see all

Publications & Presentations

PubMed

7 citations
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.
Steven E Coutre, Christopher Barnett, Olayemi Osiyemi, Daanish Hoda, Moti Ramgopal
Open Forum Infectious Diseases. 2022-05-01
158 citations
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance ...
Jean van Wyk, Faiza Ajana, Fiona Bisshop, Stéphane De Wit, Olayemi Osiyemi
Clinical Infectious Diseases. 2020-11-05
17 citations
Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study
Olayemi Osiyemi, Salih Yasin, Carmen D. Zorrilla, Ceyhun Bicer, Vera Hillewaert
Infectious Diseases and Therapy. 2018-01-15

Journal Articles

Switching to Coformulated Rilpivirine (RPV), Emtricitabine (FTC) and Tenofovir Alafenamide from Either RPV, FTC and Tenofovir Disoproxil Fumarate (TDF) or Efavirenz, F...
E S Daar, O Osiyemi, D Porter, M Thompson, C Martorell, HIV Medicine
Ceftaroline and gentamicin for the treatment of daptomycin-non-susceptible methicillin-resistant Staphylococcus aureus bacteremia and endocarditis in a pregnant patient
Nathan R. Unger, Olayemi Osiyemi, Robert M. Richardson, Jose Menajovsky and Jennifer Kuretsk, JMM Caser Reports, 1/1/2014
Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100mg administered twice daily
CD Zorrilla, R Wright, OO Osiyemi, et al, HIV Medicine. Short Communications, 1/1/2013
Effects of Darunavir/Ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks
J. Currier, C. Martorell, O. Osiyemi, M. Yin, R. Ryan, G. De La Rosa, and J. Mrus, AIDS Patient Care & STDs, 1/1/2011
Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women
F. Conradie, C. Zorilla, D. Josipovic, M. Botes, O. Osiyemi, E. Vandeloise, etc., British HIV Association, 1/1/2011
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naïve HIV type-1-infected adults
E. DeJesus, J. Lalezari, O. Osiyemi, P. Ruane, R. Ryan, T. Kakuda, J. Witek, Antiviral Therapy, 1/1/2010
Gram-positive pneumonia
Osiyemi O. and Dickinson G, Current Infectious disease reports, 1/1/2000
Epidemiologic studies & characterization of Vancomycin- resistant Enterococci recovered from a University Hospital
P. Verma, J.G. Morris, J. Hebden, Y. Smith, O. Osiyemi, M. Fullem, and R. Schwalbe, University of Maryland, 1/1/1994
Characterization of the Recombinant 47kilodalton Protein Antigen of Rickettsia tsutsugamushi expressed in Escherichia coli
E.V. Oaks, O. Osiyemi and C.K. Stover, Walter Reed Army Institute of Research, 1/1/1989
Join now to see all

Abstracts/Posters

BMS-986001 in Antiretroviral-Naïve Subjects: Evaluation of Bone and Metabolic Safety Data Through Week 48.
GA McComsey, S Guta, C Orrell, A Avihingsanon, O Osiyemi, D Stock, N Ray, SR Joshi, GJ Hanna, M Lataillade, ICAAC, 1/1/2014
Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1 Infected Pregnant Women.
Carmen Zorrilla, Rodney Wright, Olayemi Osiyemi, Salih Yasin, et al, CROI, Seattle, WA, 3/5/2012
GRACE (Gender, Race And Clinical Experience): effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.
J. Currier, C. Martorell, O. Osiyemi, M. Yin, R. Ryan, G. De La Rosa and J. Mrus., International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (ADRL), Philadelphia, PA, 10/26/2009
Pharmacokinetics and Short-term Safety and Efficacy of Once-daily Etravirine Without and With Once-daily Darunavir/ritonavir in Antiretroviral-naïve HIV-1 Infected Adu...
J. Lalezari, E. DeJesus, O. Osiyemi, P. Ruane, R. Ryan, B. Polsonetti, T. Kakuda, J. Witek, HIV DART, Rio Mar Beach, PR, 12/9/2008
Pharmacokinetics of Once-Daily Etravirine (ETR) Without and With Once-Daily Darunavir/Ritonavir (DRV/r) in Antiretroviral-Naïve HIV-1 Infected Adults.
J. Lalezari, E. DeJesus, O. Osiyemi, P. Ruane, Z. Haigney, R. Ryan, B. Polsonetti, T. Kakuda, J. Witek, Ninth International Congress on Drug Therapy in HIV Infection (HIV9), Glasgow, UK, 11/9/2008
Cerebral Phaeohyphmycosis due to a novel species.
O. Osiyemi, L. Dowdy, A. Padhye, T. Cleary and S. Mallon, University of Miami and Center for Disease Control & Prevention, 1/1/1999
Characterization of Vibrio cholerae strains by pulse field electrophoresis.
M. Trucksis, Y. Deng and O. Osiyemi, Center for Vaccine Development, University of Maryland at Baltimore, Baltimore, MD, 1/1/1995
Join now to see all

Lectures

Total and unbound pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
1/1/2014
Total and unbound darunavir pharmacokinetics in HIV-1-infected pregnant women.
Toronto, Canada - 1/14/2013

Press Mentions

'More and More' COVID-19 Cases Expected with Holidays Ahead, Doctor SaysMay 23rd, 2022
Health Care Workers 'Stressed Out' Battling COVID-19 ResurgenceAugust 4th, 2021
On the Front Lines: Unvaccinated Health Workers Put Floridians at RiskJuly 30th, 2021
Join now to see all